Skip to main content
Clinical Trials/ChiCTR1800018011
ChiCTR1800018011CompletedUnknown

阿昔洛韦地塞米松眼液治疗复发性疱疹病毒性角膜基质炎的临床研究

Not provided1 site in 1 country119 target enrollmentStarted: January 15, 2014Last updated:

Trial Snapshot

Phase
Unknown
Status
Completed
Enrollment
119
Locations
1
Primary Endpoint
最佳矫正视力

Study Overview

Brief Summary

评估阿昔洛韦地塞米松滴眼液治疗复发性疱疹病毒性角膜基质炎的临床疗效。

Study Design

Study Type
Interventional
Primary Purpose
随机平行对照
Masking
None

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 既往确诊为 HSK 三个月以上,此次复发者。

Exclusion Criteria

  • (1)严重干眼者;(2)有内眼手术史者;(3)患有其他类型的角膜炎者;(4)高眼压者;(5)高血压、糖尿病及全身系统性疾病者。

Arms & Interventions

对照组

0.1%阿昔洛韦联合妥布霉素地塞米松滴眼液(0.3%妥布霉素,0.1%地塞米松)局部点眼治疗

观察组

0.1%阿昔洛韦联合 0.06%-0.03%地塞米松滴眼液局部点眼阶梯治疗

Outcomes

Primary Outcomes

最佳矫正视力

角膜混浊范围及深度

中央角膜厚度

眼内压

角膜内皮细胞密度

局部用药时间

Secondary Outcomes

No secondary outcomes reported

Investigators

Study Sites (1)

Loading locations...

Similar Trials